Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
INTERMITTENT CONTINUOUS-INFUSION OF IFOSFAMIDE AND 5-FLUOROURACIL IN PATIENTS WITH ADVANCED ADENOCARCINOMA OF THE PANCREAS
Autore:
POORTER RL; BAKKER PJM; HUIZING MT; TAAT CW; RIETBROEK RC; GOUMA DJ; RAUWS EAJ; VEENHOF CHN;
Indirizzi:
UNIV AMSTERDAM,ACAD MED CTR,DEPT MED ONCOL,POB 22700 1100 DE AMSTERDAM NETHERLANDS UNIV AMSTERDAM,ACAD MED CTR,DEPT SURG 1100 DE AMSTERDAM NETHERLANDS UNIV AMSTERDAM,ACAD MED CTR,DEPT GASTROENTEROL 1100 DE AMSTERDAM NETHERLANDS
Titolo Testata:
Annals of oncology
fascicolo: 10, volume: 6, anno: 1995,
pagine: 1048 - 1049
SICI:
0923-7534(1995)6:10<1048:ICOIA5>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Soggetto:
PHASE-II; CANCER;
Keywords:
CHEMOTHERAPY; CONTINUOUS INFUSION; 5-FLUOROURACIL; IFOSFAMIDE; PANCREATIC CANCER;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
11
Recensione:
Indirizzi per estratti:
Citazione:
R.L. Poorter et al., "INTERMITTENT CONTINUOUS-INFUSION OF IFOSFAMIDE AND 5-FLUOROURACIL IN PATIENTS WITH ADVANCED ADENOCARCINOMA OF THE PANCREAS", Annals of oncology, 6(10), 1995, pp. 1048-1049

Abstract

Background: In advanced adenocarcinoma of the pancreas treatment with5-fluorouracil (5-FU) or ifosfamide results in response rates of approximately 20%. Continuous infusion of these drugs is on many grounds theoretically attractive and may therefore offer advantages over bolus or short-term infusion. Patients and methods: Sixteen patients with advanced adenocarcinoma of the pancreas with progressive measurable disease and no previous chemotherapy entered the study. After implantationof a subcutaneous infusion chamber patients were treated on days 1-12with ifosfamide (1.0 g/m(2)/day) and 5-FU (300 mg/m(2)/day) as a continuous intravenous infusion using a portable infusion pump. Mesna (1.0g/m(2)/day) was added as uroprotective agent from day 1-14. Courses were repeated every 4 weeks. Results: Fifteen of the 16 patients were evaluable for response. One partial response was observed (response rate 7% [95% CI: 0%-32%]). Toxicity occurred in 64% of the courses. Dose limiting toxic effects were grade 3 nausea/vomiting (WHO) in 3 patients, grade 2 mucositis in 1 patient and grade 3 leukopenia in 1 patient. Conclusion: Intermittent continuous infusion with ifosfamide, mesna and 5-FU is feasible on an outpatient basis. Although continuous infusion of ifosfamide may have a more favorable toxicity profile, the combination of 5-FU and ifosfamide in this schedule is no more effective than bolus or short-term infusion.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 06/04/20 alle ore 01:38:00